DGAP-News: Eckert & Ziegler Strahlen- und Medizintechnik AG / Key word(s): Alliance 
Eckert & Ziegler and Telix Pharmaceuticals Enter Co-Promotion Agreement for Prostate Cancer Diagnostic in the United 
States 
2021-06-03 / 08:07 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Berlin, 3 June 2021. Eckert & Ziegler (ISIN DE0005659700, TecDAX) and Telix Pharmaceuticals (Telix) will cooperate 
closely in the commercialization of GalliaPharm^(R) (^68Ge/^68Ga Generator) and investigational product Illuccix^(R) 
(Kit for the preparation of Ga-68 PSMA-11 injection) in the United States. An agreement to this effect has now been 
signed by the two companies. Illuccix^(R) is a preparation for imaging prostate cancer by positron emission tomography 
(PET) and is currently under review for regulatory approval in the United States and multiple markets worldwide. 
Eckert & Ziegler and Telix will expand their existing collaboration to further develop access to Ga-68 supply in the 
United States. The parties will both promote the combination of GalliaPharm^(R) and Illuccix^(R) to national 
radiopharmacy networks, commercial and hospital-based nuclear pharmacies, and other target institutions. 
"After previously being granted distribution rights for Germany, our home market, the latest collaboration marks 
another important milestone for our ^68Ga generator GalliaPharm^(R) and our nuclear medicine activities", explained Dr 
Harald Hasselmann, Eckert & Ziegler Executive Director and responsible for the Medical segment. "We are pleased to have 
Telix as a partner and to be able to jointly provide leading edge diagnostic products to prostate cancer patients in 
the USA." 
"This important cooperation between EZAG and Telix sales teams is highly complementary to our efforts in rolling out ^ 
68Ga-PSMA imaging across the US. Subject to FDA approval, we will together raise awareness of this state-of-the-art 
imaging modality and facilitate coast-to-coast access for US men living with prostate cancer.", added Telix Americas 
President Dr Bernard Lambert. 
Following regulatory approval, Illuccix^(R) will be offered as a cold kit preparation for the diagnosis of prostate 
cancer. For this purpose, Illuccix^(R) enables PSMA-11 to be radio-labelled with the radionuclide ^68Ga directly before 
injection by medical personnel. After preparing the radiopharmaceutical and injecting it into the patient, sites 
exhibiting prostate cancer are localized and imaged via the presence of the prostate-specific membrane antigen.^[1],[2] 
Prostate cancer is the most common type of cancer in men in the United States, with approximately 210,000 cases in 
2020, a significantly higher incidence than either lung cancer (116,000 new cases) or bowel cancer (82,000 new cases).^ 
[3] Prostate cancer was also the second most common cause of cancer death in men, with over 32,000 men dying from the 
disease in the United States in 2020. More than 812,000 American men were estimated to be living with prostate cancer 
in 2020. 
[1] Fendler W et al. JAMA Oncol. 2019; 5(6): 856-863. 
[2] Hofman M et al. The Lancet. 2020; 395: 1208-1216. 
[3] IARC Global Cancer Observatory, 2020. 
About Eckert & Ziegler 
Eckert & Ziegler Strahlen- und Medizintechnik AG with around 800 employees, is one of the world's largest providers of 
isotope-related components for nuclear medicine and radiation therapy. The company offers services for 
radiopharmaceuticals at its worldwide locations, from early development to commercialization. Eckert & Ziegler shares 
(ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse. 
Contributing to saving lives. 
About Telix Pharmaceuticals 
Telix is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products 
using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with international 
operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage products that 
address significant unmet medical needs in oncology and rare diseases. Telix is listed on the Australian Securities 
Exchange (ASX: TLX). For more information visit www.telixpharma.com and follow Telix on Twitter (@TelixPharma) and 
LinkedIn. 
About Illuccix^(R) 
Telix's lead investigational product, Illuccix^(R) (TLX591-CDx) for prostate cancer imaging, has been accepted for 
filing by the U.S. FDA, and is under priority evaluation by the Australian Therapeutic Goods Administration (TGA). 
Telix is also progressing marketing authorisation applications for Illuccix^(R) in the European Union and Canada. None 
of Telix's products have received a marketing authorisation in any jurisdiction. 
Eckert & Ziegler AG Contact: 
Karolin Riehle, Investor Relations 
Robert-Rössle-Str. 10, 13125 Berlin, Germany 
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 
Telix Pharmaceuticals Contact: 
Dr. Stewart Holmstrom, Investor Relations 
Suite 401, 55 Flemington Road, North Melbourne, VIC 3051, Australia 
Email: stewart.holmstrom@telixpharma.com 
=---------------------------------------------------------------------------------------------------------------------- 
2021-06-03 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      Eckert & Ziegler Strahlen- und Medizintechnik AG 
              Robert-Rössle-Str.10 
              13125 Berlin 
              Germany 
Phone:        +49 30 941084-138 
Fax:          +49 30 941084-112 
E-mail:       karolin.riehle@ezag.de 
Internet:     www.ezag.de 
ISIN:         DE0005659700 
WKN:          565970 
Indices:      SDAX 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1203887 
 
End of News   DGAP News Service 
=------------

1203887 2021-06-03


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1203887&application_name=news

(END) Dow Jones Newswires

June 03, 2021 02:08 ET (06:08 GMT)